

FORM PTO-1449

ATTY. DOCKET NO.  
1483.0340003/JMC/JSL

APPLICATION NO.  
10/772,445

FIRST NAMED INVENTOR  
Upasani *et al.*

FILING DATE  
February 6, 2004

ART UNIT  
1615

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,748,331	06/24/1973	Cooke <i>et al.</i>			05/06/1971
	AB1	3,963,717	06/15/1976	Cooke <i>et al.</i>			03/10/1975
	AC1	5,284,957	02/08/1994	Huff			09/03/1992
	AD1	5,514,680	05/07/1996	Weber <i>et al.</i>			11/05/1993
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 94/13275	06/23/1993	WIPO			Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

### OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Anderson, B.A. <i>et al.</i> , "Application of a Practical Biocatalytic Reduction to an Enantioselective Synthesis of the 5H-2,3-Benzodiazepine LY300164," <i>J. Am. Chem. Soc.</i> 117:12358-12359, American Chemical Society (1995)
	AS	1	Buchan, A.M. <i>et al.</i> , "Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia," <i>Neuroreport</i> 2:473-476, Lippincott, Williams & Wilkins (1991)
	AT	1	Buchan, A.M. <i>et al.</i> , "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?" <i>Stroke Suppl.</i> 1 24:I-148-I-154, Lippincott, Williams & Wilkins (1993)

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
	FIRST NAMED INVENTOR Upasani <i>et al.</i>	
	FILING DATE February 6, 2004	ART UNIT 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Choi, D.W. et al., "Glutamate Neurotoxicity in Cortical Cell Culture," <i>J. Neurosci</i> 7:357-368, Society for Neuroscience (1987)
	AS	2	Coombs, R.V. et al., "Synthesis and Antiinflammatory Activity of 1-Alkyl-4-aryl-2(1H)-quinazolinones and Quinazolinethiones," <i>J. Med. Chem.</i> 16:1237-1245, American Chemical Society (1973)
	AT	2	Copani, A. et al., "Nootropic Drugs Positively Modulate $\gamma$ -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid-Sensitive Glutamate Receptors in Neuronal Cultures," <i>J. Neurochem.</i> 58:1199-1204, The International Society for Neurochemistry (1992)

EXAMINER /Cecilia Jaisle/	DATE CONSIDERED 08/02/2008
---------------------------	----------------------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1483.0340003/JMC/JSLAPPLICATION NO.  
10/772,445FIRST NAMED INVENTOR  
Upasani *et al.*FILING DATE  
February 6, 2004ART UNIT  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	De Sarro, G. et al., "GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice," <i>Eur. J. Pharmacol.</i> 294:411-422, Elsevier Science (1995)
	AS	<u>3</u>	Fetter, J. et al., "Electron Deficient Heteroaromatic Ammonioamidates-XVI," <i>Tetrahedron</i> 34:2557-2563, Pergamon Press (1978)
	AT	<u>3</u>	Graham, S.H. et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," <i>J. Pharm. Exp. Ther.</i> 276:1-4, American Society for Pharmacology and Experimental Therapeutics (1996)

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1483.0340003/JMC/JSLAPPLICATION NO.  
10/772,445FIRST NAMED INVENTOR  
Upasani *et al.*FILING DATE  
February 6, 2004ART UNIT  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Haider, N., "Convenient Synthesis of Cycloalkene-Fused Phthalazinones," <i>Heterocycles</i> 41:2519-2525, Sendai Institute of Heterocyclic Chemistry (1995)
	AS	<u>4</u>	Houlihan, W.J. et al., "Antiinflammatory Properties of 8-Aryl-5-isopropyl-2H-1,3-dioxolo[4,5-g]quinazolin-6(5H)-ones and -thiones," <i>J. Med. Chem.</i> 25:1110-1113, American Chemical Society (1982)
	AT	<u>4</u>	Hunter, J.C. and L. Singh, "Role of excitatory amino acid receptors in the mediation of the nociceptive response to formalin in the rat," <i>Neurosci Lett.</i> 174:217-221, Elsevier Scientific Publishers (1994)

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
	FIRST NAMED INVENTOR Upasani <i>et al.</i>	
	FILING DATE February 6, 2004	ART UNIT 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>5</u>	Ikeda, A. et al., "Clinical Trial of Piracetam in Patients with Myoclonus: Nationwide Multiinstitution Study in Japan," <i>Movement Disorders</i> 11:691-700, Raven Press (1996)
AS	<u>5</u>	Iwasaki, Y. et al., "CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats," <i>J. Neurol. Sci.</i> 134:21-25, Society for Neuroscience (1995)
AT	<u>5</u>	Jones, B.J. et al., "The potential anxiolytic activity of GR38032F, a 5-HT <sub>3</sub> -receptor antagonist," <i>Br. J. Pharmacol.</i> 93:985-993, Macmillan Journals Ltd. (1988)

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED	08/02/2008
----------	------------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1483.0340003/JMC/JSLAPPLICATION NO.  
10/772,445FIRST NAMED INVENTOR  
Upasani *et al.*FILING DATE  
February 6, 2004ART UNIT  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>6</u>	Keana, J.F.W. et al., "Synthesis and Structure-Activity Relationships of Substituted 1,4-Dihydroquinoxaline-2,3-diones: Antagonists of N-Methyl-D-aspartate (NMDA) Receptor Glycine Sites and Non-NMDA Glutamate Receptors," <i>J. Med. Chem.</i> 38:4367-4379, American Chemical Society (1995)
	AS	<u>6</u>	Larson, J. et al., "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats," <i>Brain Res.</i> 738:353-356, Elsevier/North-Holland Biomedical Press (1996)
	AT	<u>6</u>	Le Peillet, E. et al., "The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat," <i>Brain Res.</i> 571:115-120, Elsevier/North-Holland Biomedical Press (1992)

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
	FIRST NAMED INVENTOR Upasani <i>et al.</i>	
	FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>  </u>	Lipton, S. and P.A. Rosenberg, "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders," <i>N. Engl. J. Med.</i> 330:613-622, Massachusetts Medical Society (1994)
	AS	<u>  </u>	McDonald, J.W. et al., "Physiological and pathophysiological roles of excitatory amino acids during central nervous system development," <i>Brain Res. Rev.</i> 15:41-70, Elsevier Science (1990)
	AT	<u>  </u>	Pelletier, J.C. et al., "Substituted 1,2-Dihydrophthalazines: Potent, Selective, and Noncompetitive Inhibitors of the AMPA Receptor," <i>J. Med. Chem.</i> 39:343-346, American Chemical Society (1996)

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED	08/02/2008
----------	------------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

FORM PTO-1449  <b>INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
	FIRST NAMED INVENTOR Upasani <i>et al.</i>	
	FILING DATE February 6, 2004	ART UNIT 1615

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

	AR	<u>8</u>	Sang, C.N. et al., "Analgesic Effects of AMPA/Kainate Antagonist LY293558 in Human: Reduction of Capsaicin-Evoked Allodynia and Hyperalgesia But Not Pain Sensations In Normal Skin," <i>Soc. Neurosci</i> 23:1015, Abstract No. 401.14, Society of Neuroscience (October 1997)
	AS	<u>8</u>	Schoepp, D. et al., "Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors," <i>Trends Pharm Sci</i> 11:508-515, Elsevier in Association with the International Union of Pharmacology (1990)
	AT	<u>8</u>	Sheardown, M.J. et al., "2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxalin: A Neuroprotectant for Cerebral Ischemia," <i>Science</i> 247:571-574, American Association for the Advancement of Science (1990)

EXAMINER /Cecilia Jaisle/	DATE CONSIDERED 08/02/2008
---------------------------	----------------------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./



FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
	FIRST NAMED INVENTOR Upasani <i>et al.</i>	
	FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	<u>9</u>	Sheardown, M.J. et al., "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," Eur. J. Pharmacol. 236:347-353, Elsevier Science (1993)	
AS	<u>9</u>	Staubli, U. et al., "Facilitation of glutamate receptors enhances memory," Proc. Natl. Acad. Sci. USA 91:777-781, National Academy of Sciences (1994)	
AT	<u>9</u>	Thomas, R.J., "Excitatory Amino Acids in Health and Disease," J. Am. Geriatr. Soc. 43:1279-1289, Blackwell Science (1995)	

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED 08/02/2008
----------	------------------	----------------------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1483.0340003/JMC/JSLAPPLICATION NO.  
10/772,445FIRST NAMED INVENTOR  
Upasani *et al.*FILING DATE  
February 6, 2004ART UNIT  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AR	<u>10</u>	Woodward, R.M. et al., "In Vitro Pharmacology of ACEA-1021 and ACEA-1031: Systemically Active Quinoxalinediones with High Affinity and Selectivity for N-Methyl-D-aspartate Receptor Glycine Sites," <i>Mol. Pharmacol.</i> 47:568-581, American Society for Pharmacology and Experimental Therapeutics (1995)
	AS	<u>10</u>	Wrathall, J.R. et al., "Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-Methyl-D-Aspartate receptors," <i>Exp. Neurology</i> 137:119-126, Academic Press (1996)
	AT		

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./



FORM PTO-1449

ATTY. DOCKET NO.  
1483.0340003/JMC/JSLAPPLICATION NO.  
10/772,445SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENTFIRST NAMED INVENTOR  
Upasani *et al.*FILING DATE  
February 6, 2004ART UNIT  
1516

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM2	JP S51-8287	01/23/1976	Japan			X Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>11</u>	English language translation of Japanese Unexamined Patent Application No. JP S51-8287 published January 23, 1976, 7 pages. (Document AM2)
	AS	<u>11</u>	Yamamoto, M., et al., "Quinazolin-2-ones from 3,4-dihydroquinazolin-2-ones," <i>Chem. Abstr.</i> 84:586, Abstract No. 180277m, American Chemical Society (1976)
	AT	<u>11</u>	Supplementary Partial European Search Report for European Application No. EP99911063 filed on March 2, 1999

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.  
1483.0340003/JMC/JSLAPPLICATION NO.  
10/772,445FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENTFIRST NAMED INVENTOR  
Upasani *et al.*FILING DATE  
February 6, 2004ART UNIT  
1516

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE1	3,759,920	09/18/1973	Linder <i>et al.</i>			06/24/1971
	AF1	3,856,960	12/24/1974	Cooke <i>et al.</i>			04/13/1973
	AG1	4,224,328	09/23/1980	Takesue			04/11/1979
	AH1	5,650,410	07/22/1997	Sohda <i>et al.</i>			04/17/1995
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM1	DE 2 058 722	06/09/1971	Germany			X Yes No
	AN1	DE 2 307 808	08/30/1973	Germany			Yes X No
	AO1	GB 1341401	12/19/1993	Great Britain			Yes No
	AP1	EP 0 567 107 A1	10/27/1993	Europe			Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT	<u>10</u>	Dialog File 351, Accession No. 1973-41080U/197329, Derwent WPI English language abstract for DE 2 307 808 (Document AN1)

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
1483.0340003/JMC/JSLAPPLICATION NO.  
10/772,445FIRST NAMED INVENTOR  
Upasani *et al.*FILING DATE  
February 6, 2004ART UNIT  
1516

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	EP 0 634 169 A1	01/18/1995	Europe			Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER /Cecilia Jaisle/

DATE CONSIDERED 08/02/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.